In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price target of $230.00. The company’s shares closed yesterday at $110.75.
Prasad covers the Healthcare sector, focusing on stocks such as Zoetis, Jazz Pharmaceuticals, and Organon. According to TipRanks, Prasad has an average return of 1.0% and a 42.76% success rate on recommended stocks.
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $189.92.
The company has a one-year high of $146.70 and a one-year low of $106.61. Currently, Jazz Pharmaceuticals has an average volume of 605.6K.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals (JAZZ) Company Description:
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Read More on JAZZ:
- JAZZ Earnings this Week: How Will it Perform?
- Jazz completes rolling submission of BLA for zanidatamab antibody
- Jazz Pharmaceuticals price target raised to $188 from $171 at Piper Sandler
- Jazz Pharmaceuticals price target raised to $230 from $225 at Stifel
- Zymeworks price target raised to $14 from $12 at Wells Fargo
